Aldeyra Therapeutics Inc.

05/24/2022 | Press release | Distributed by Public on 05/24/2022 05:08

Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease